Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: a double-blind randomized placebo–control study

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Neuropsychopharmacology

• Publication date

  2019-08-17

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1038/s41386-019-0480-yPMID 31421635PMCID PMC6898334
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial.

  2019cited by this paper
• Validity of the Maudsley Staging Method in Predicting Treatment-Resistant Depression Outcome Using the Netherlands Study of Depression and Anxiety.

  2018cited by this paper
• Glutamatergic Modulators in Depression

  2018cited by this paper
• d‐Cycloserine facilitates fear extinction in adolescent rats and differentially affects medial and lateral prefrontal cortex activation

  2018cited by this paper
• The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis.

  2017cited by this paper
• Ketamine accelerates fear extinction via mTORC1 signaling.

  2017cited by this paper
• Ketamine for Depression, 4: In What Dose, at What Rate, by What Route, for How Long, and at What Frequency?

  2017cited by this paper
• Dose-Related Effects of Adjunctive Ketamine in Taiwanese Patients with Treatment-Resistant Depression

  2017cited by this paper
• Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories

  2016cited by this paper
• The NMDA receptor partial agonist d-cycloserine does not enhance motor learning

  2016cited by this paper
• Treatment-resistant bipolar depression: a randomized controlled trial of electroconvulsive therapy versus algorithm-based pharmacological treatment.

  2015cited by this paper
• Maintaining the initial clinical response after ketamine in bipolar and unipolar depression: an important next-step challenge.

  2015cited by this paper
• Single-dose ketamine followed by daily D-Cycloserine in treatment-resistant bipolar depression.

  2015cited by this paper
• Combining d-cycloserine with motor training does not result in improved general motor learning in neurologically intact people or in people with stroke.

  2014cited by this paper
• Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression.

  2014cited by this paper
• Randomized Placebo-Controlled D-Cycloserine with Cognitive Behavior Therapy for Pediatric Posttraumatic Stress

  2014cited by this paper
• Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond.

  2013cited by this paper
• Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.

  2013cited by this paper
• Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.

  2013cited by this paper
• Effect of D‐cycloserine in conjunction with fear extinction training on extracellular signal‐regulated kinase activation in the medial prefrontal cortex and amygdala in rat

  2013cited by this paper
• Serial infusions of low-dose ketamine for major depression

  2013cited by this paper
• A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression.

  2013cited by this paper
• Evidence‐based options for treatment‐resistant adult bipolar disorder patients

  2012cited by this paper
• Impaired Executive Function in Contemplated and Attempted Suicide in Late Life.

  2012cited by this paper
• Treatment-resistant depression: therapeutic trends, challenges, and future directions

  2012cited by this paper
• Sequenced Treatment Alternatives to Relieve Depression (STAR*D). Part 2: Study outcomes.

  2008cited by this paper
• Sequenced Treatment Alternatives to Relieve Depression (STAR*D). Part 1: study design.

  2008cited by this paper
• Deficit of NMDA receptor activation in CA1 hippocampal area of aged rats is rescued by d‐cycloserine

  2007cited by this paper
• Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder.

  2006cited by this paper
• Treatment-resistant bipolar disorder

  2006cited by this paper
• Effects of D-cycloserine on extinction: translation from preclinical to clinical work.

  2006cited by this paper
• Memantine may acutely improve cognition and have a mood stabilizing effect in treatment-resistant bipolar disorder.

  2006cited by this paper
• D‐Cycloserine facilitates synaptic plasticity but impairs glutamatergic neurotransmission in rat hippocampal slices

  2003cited by this paper
• Subunit specificity and mechanism of action of NMDA partial agonist D-cycloserine.

  2001cited by this paper
• Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications.

  1998cited by this paper
• The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.

  1998cited by this paper
• A RATING SCALE FOR DEPRESSION

  1960cited by this paper

• Transforming treatment-resistant depression (TRD) care in the Gulf Cooperation Council (GCC) countries: a narrative review of emerging therapies, advancements, and implementation barriers

  2026influential citation
• Using Classification and Regression Tree Modeling to Investigate the Effects of Subanesthetic Ketamine Infusion on Remission of Suicidal Symptoms

  2025cites this paper
• Exploring effects of chronic d‐cycloserine administration on expression of GluN2 subunits and tripartite synaptic transmission in thalamocortical pathway

  2025influential citation
• Enriched environment prevented glutamate receptor loss in the prefrontal cortex to alleviate CUMS-induced depression-like behaviors.

  2025cites this paper
• Novel perspectives for glutamatergic strategies, psychedelics and antipsychotic augmentation in Treatment Resistant Depression: A narrative review

  2025cites this paper
• Effect of Perioperative Subanesthetic Dose of Esketamine on Postoperative Recovery Quality in Patients Undergoing Laparoscopic Gastrointestinal Surgery: A Randomised, Double-Blind, Controlled Trial

  2025cites this paper
• D-cycloserine effects on COPD and depression in a murine experimental model

  2025cites this paper
• Adjunctive d-serine treatment for major depressive disorder: A randomized clinical trial.

  2025cites this paper
• PROPHYLACTIC KETAMINE: CURRENT KNOWLEDGE AND FUTURE DIRECTIONS.

  2025cites this paper
• A comparative study of blood and hippocampal D-serine change patterns in drug-naïve patients and animal models of depression.

  2025cites this paper
• Emerging Medications for Treatment-Resistant Depression: A Review with Perspective on Mechanisms and Challenges

  2025cites this paper
• Design of (R)-3-(5-Thienyl)carboxamido-2-aminopropanoic Acid Derivatives as Novel NMDA Receptor Glycine Site Agonists: Variation in Molecular Geometry to Improve Potency and Augment GluN2 Subunit-Specific Activity

  2025cites this paper
• Intermittent theta-burst stimulation with adjunctive D-cycloserine rapidly resolves suicidal ideation and decreases implicit association with death/suicide

  2025cites this paper
• Clinical Trials Studying Suicide Risk Reduction: Who is Excluded From Participation

  2024cites this paper
• Rapid Antidepressant and Antisuicidal Effects of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression With or Without Low-Grade Inflammation

  2024influential citation
• Synergistic behavioral and neuroplastic effects of psilocybin-NMDAR modulator administration

  2024cites this paper
• Advancements in NMDA Receptor-Targeted Antidepressants: From d-Cycloserine Discovery to Preclinical Efficacy of Lu AF90103.

  2024cites this paper
• NMDAR Down-Regulation: Dual – Hit Molecular Target For COPD – Depression Comorbidity

  2024cites this paper
• Recent advances in the synthesis of antidepressant derivatives: pharmacologic insights for mood disorders

  2024influential citation
• [Targeting NMDAR/AMPAR: a promising pharmacotherapeutic approach for depressive disorders].

  2024cites this paper
• Treat bipolar depression with atypical antipsychotics and mood stabilisers; new therapies require further study

  2024cites this paper
• d-Cycloserine enhances the bidirectional range of NMDAR-dependent hippocampal synaptic plasticity

  2024cites this paper
• A systematic review of the incidence of medical serious adverse events in sub-anesthetic ketamine treatment of psychiatric disorders.

  2023cites this paper
• Targeting NMDA receptor signaling for therapeutic intervention in brain disorders

  2023cites this paper
• Glutamatergic Neurotransmission: A Potential Pharmacotherapeutic Target for the Treatment of Cognitive Disorders.

  2023cites this paper
• Antidepressant and anti-suicidal effects of ketamine in treatment-resistant depression associated with psychiatric and personality comorbidities: A double-blind randomized trial.

  2023cites this paper
• Pharmacotherapies for Treatment-Resistant Depression: How Antipsychotics Fit in the Rapidly Evolving Therapeutic Landscape.

  2023cites this paper
• New Pharmacologic Approaches to the Treatment of Bipolar Depression

  2023cites this paper
• Clínicas de ketamina: usos actuales según la evidencia

  2023cites this paper
• D-cycloserine is not susceptible to self-administration using an intravenous self-administration model in male ketamine-habituated Sprague-Dawley rats.

  2023cites this paper
• Ketamine in neuropsychiatric disorders: an update

  2023cites this paper
• The why, when, where, how, and so what of so-called rapidly acting antidepressants

  2023cites this paper
• Association of Neurofilament Light Chain With the Antidepressant Effects of Low-Dose Ketamine Infusion Among Patients With Treatment-Resistant Depression

  2023cites this paper
• Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression

  2023cites this paper
• Synergistic psychedelic - NMDAR modulator treatment for neuropsychiatric disorders

  2023cites this paper
• Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments

  2023cites this paper
• Short-term ketamine use in bipolar depression: a review of the evidence for short-term treatment management

  2023cites this paper
• Clinical effects of low‐dose esketamine for anaesthesia induction in the elderly: A randomized controlled trial

  2022cites this paper
• Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic system.

  2022cites this paper
• The effect of ketamine and D-cycloserine on the high frequency resting EEG spectrum in humans

  2022cites this paper
• NRX-101, a Rapid-Acting Anti-Depressant, Does Not Cause Neurotoxicity Following Ketamine Administration in Preclinical Models

  2022cites this paper
• Efficacy of Adjunctive D-Cycloserine to Intermittent Theta-Burst Stimulation for Major Depressive Disorder: A Randomized Clinical Trial.

  2022cites this paper
• An open-label study evaluating the safety, behavioral, and electrophysiological outcomes of low-dose ketamine in children with ADNP syndrome

  2022cites this paper
• NRX-101 (D-cycloserine plus lurasidone) vs. lurasidone for the maintenance of initial stabilization after ketamine in patients with severe bipolar depression with acute suicidal ideation and behavior: a randomized prospective phase 2 trial

  2022influential citation
• Modulating Ketamine’s Locomotor Activating and Reinforcing Effects Through Drug Combinations

  2022cites this paper
• SYSTEMATIC REVIEW AND META-ANALYSIS Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis

  2022cites this paper
• Baihe Dihuang (Lilium Henryi Baker and Rehmannia Glutinosa) decoction attenuates somatostatin interneurons deficits in prefrontal cortex of depression via miRNA-144-3p mediated GABA synthesis and release.

  2022cites this paper
• Intrinsic Connectivity Networks of Glutamate-Mediated Antidepressant Response: A Neuroimaging Review

  2022cites this paper
• Investigational Drugs for the Treatment of Depression (Part 2): Glutamatergic, Cholinergic, Sestrin Modulators, and Other Agents

  2022cites this paper
• Genetic variables of the glutamatergic system associated with treatment-resistant depression: A review of the literature

  2022cites this paper
• Antibiotics and mental health: The good, the bad and the ugly

  2022cites this paper
• Ketamine and Other Glutamate Receptor Antagonists As Fast-Actin

  2022cites this paper
• Ketamine for Bipolar Depression: A Systematic Review

  2021cites this paper
• Strategies to Prolong Ketamine’s Efficacy in Adults with Treatment-Resistant Depression

  2021cites this paper
• Targeting the dysfunction of glutamate receptors for the development of novel antidepressants.

  2021cites this paper
• Suicidality Associated With Deep Brain Stimulation in Extrapyramidal Diseases: A Critical Review and Hypotheses on Neuroanatomical and Neuroimmune Mechanisms

  2021cites this paper
• Efficacy of ketamine for major depressive episodes at 2, 4, and 6-weeks post-treatment: A meta-analysis

  2021cites this paper
• Advances in the psychopharmacotherapy of bipolar disorder type I

  2021cites this paper
• The Role for GABAergic Interneurons Subtypes in the Antidepressant Efficacy of Traditional Chinese Medicine Formula Lily Bulb and Rehmannia Decoction

  2021cites this paper
• Is one or two infusions better in the first week of low-dose ketamine treatment for medication-resistant depression? A post hoc pooled analysis of randomized placebo-controlled and open-label trials.

  2021cites this paper
• Low‐dose ketamine infusion in treatment‐resistant double depression: Revisiting the adjunctive ketamine study of Taiwanese patients with treatment‐resistant depression

  2021cites this paper
• The rapid anti-suicidal ideation effect of ketamine: A systematic review.

  2021cites this paper
• Ventromedial prefrontal cortex/anterior cingulate cortex Glx, glutamate, and GABA levels in medication-free major depressive disorder

  2021cites this paper
• Relationship of Brain Glutamate Response to D-Cycloserine and Lurasidone to Antidepressant Response in Bipolar Depression: A Pilot Study

  2021cites this paper
• Treatment-resistant bipolar depression: concepts and challenges for novel interventions

  2021cites this paper
• Next-Step Treatment Considerations for Patients With Treatment-Resistant Depression That Responds to Low-Dose Intravenous Ketamine.

  2020cites this paper
• Increased use of ketamine for the treatment of depression: Benefits and concerns.

  2020cites this paper
• Intracellular Signaling Cascades in Bipolar Disorder.

  2020cites this paper
• Age affects temporal response, but not durability, to serial ketamine infusions for treatment refractory depression

  2020cites this paper
• A Randomized Trial of the N-methyl-d-aspartate Receptor Glycine Site Antagonist Prodrug 4-chlorokynurenine in Treatment-Resistant Depression.

  2020cites this paper
• Glutamatergic dysregulation in mood disorders: opportunities for the discovery of novel drug targets

  2020cites this paper
• New agents and perspectives in the pharmacological treatment of major depressive disorder.

  2020cites this paper
• Using classification and regression tree modelling to investigate treatment response to a single low-dose ketamine infusion: Post hoc pooled analyses of randomized placebo-controlled and open-label trials.

  2020cites this paper
• Neurofilament light chain: emerging evidence in neuropsychiatric disorders

  year unknowncites this paper